<div id="readability-page-1"><p>Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $65.00.</p><h3>Introducing TipRanks MCP for Agents</h3><ul><li> Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. </li><li>Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.</li></ul> <p>Bansal covers the Healthcare sector, focusing on stocks such as Merck &amp; Company, Pfizer, and Eli Lilly &amp; Co. According to TipRanks, Bansal has an average return of <span>9.2%</span> and a 56.81% success rate on recommended stocks. </p> <p>In a report released on June 5, Guggenheim also reiterated a Buy rating on the stock with a $56.00 price target.</p></div>

TVTX

<p>Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics (TVTX) with a $65 price target. Additionally, Guggenheim reiterated a Buy rating on the stock with a $56 price target in a June 5 report.</p>

Tip Ranks

Travere Therapeutics

Wells Fargo

Merck

Pfizer

Eli Lilly

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo